Health Care | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals
NASDAQ | Common Stock
GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform in various disease areas.
Its lead product is Epidiolex, an oral medicine for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex.
The company also develops and markets Sativex for the treatment of spasticity due to multiple sclerosis.
In addition, it develops various product candidates for the treatment of schizophrenia, autism spectrum disorder, neuropsychiatric symptom, and neonatal hypoxic ischemic encephalopathy.
It primarily operates in Europe, the United Kingdom, the United States, and internationally.
GW Pharmaceuticals plc was founded in 1998 and is based in Cambridge, the United Kingdom.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 3, 21 | -0.05 Decreased by -150.00% | -0.36 Increased by +86.11% |
| Feb 16, 21 | -0.08 Decreased by -14.29% | -0.05 Decreased by -47.06% |
| Nov 3, 20 | -0.03 Increased by +25.00% | -0.06 Increased by +46.43% |
| Aug 6, 20 | -0.02 Increased by +69.04% | -0.04 Increased by +50.12% |
| May 11, 20 | -0.02 Increased by +85.71% | -0.07 Increased by +71.10% |
| Feb 25, 20 | -0.07 Increased by +97.08% | -0.03 Decreased by -143.90% |
| Nov 5, 19 | -0.04 Increased by +82.61% | -0.06 Increased by +36.71% |
| Aug 6, 19 | -0.06 Increased by +94.87% | 0.03 Decreased by -301.25% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 21 | 152.47 M Increased by +26.39% | -19.68 M Decreased by -147.04% | Decreased by -12.91% Decreased by -95.46% |
| Dec 31, 20 | 148.22 M Increased by +35.89% | -29.15 M Decreased by -16.84% | Decreased by -19.66% Increased by +14.02% |
| Sep 30, 20 | 137.05 M Increased by +50.66% | -12.19 M Increased by +11.41% | Decreased by -8.89% Increased by +41.19% |
| Jun 30, 20 | 121.30 M Increased by +68.38% | -8.83 M Decreased by -111.07% | Decreased by -7.28% Decreased by -106.57% |
| Mar 31, 20 | 120.63 M Increased by +207.37% | -7.96 M Increased by +84.09% | Decreased by -6.60% Increased by +94.82% |
| Dec 31, 19 | 109.08 M Increased by +462.51% | -24.95 M Increased by +92.69% | Decreased by -22.87% Increased by +98.70% |
| Sep 30, 19 | 90.97 M Increased by +7.04 K% | -13.76 M Increased by +88.22% | Decreased by -15.12% Increased by +99.84% |
| Jun 30, 19 | 72.04 M Increased by +2.65 K% | 79.75 M Increased by +394.36% | Increased by +110.70% Increased by +110.72% |